sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta Will Resume Gene Therapy Shipments

· 8h · on MSN

FDA Says Sarepta Can Resume Gene Therapy in Some Patients

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again.

Continue reading

· 5h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

FDA allows Sarepta to resume some Elevidys shipments

Investing.com South Africa9h

Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD

Elevidys is an adeno-associated virus vector-based gene therapy that uses Sarepta’s AAVrh74 Platform Technology to treat DMD, ...

18h

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy ...

16hon MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

News Nation on MSN15h

Parents urge FDA to restore gene therapy after distribution pause

A recent FDA investigation has paused further distribution of Elevidys, following reports of at least three patient deaths.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results